Page last updated: 2024-09-04

tipifarnib and Dermatitis Medicamentosa

tipifarnib has been researched along with Dermatitis Medicamentosa in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Albitar, M; Cortes, J; Garcia-Manero, G; Giles, F; Kantarjian, H; Koller, C; Kurzrock, R; O'Brien, S; Rackoff, W; Talpaz, M; Thibault, A; Thomas, D	1
Arceci, RJ; Balis, FM; Blaney, SM; End, D; Fox, E; Gillespie, A; Jayaprakash, N; Palumbo, JS; Pitney, A; Salzer, WL; Whitcomb, P; Widemann, BC; Zannikos, P	1

Trials

2 trial(s) available for tipifarnib and Dermatitis Medicamentosa

Article	Year
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood, 2003, Mar-01, Volume: 101, Issue:5 Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Blast Crisis; Drug Administration Schedule; Drug Eruptions; Endothelial Growth Factors; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Fibroblast Growth Factor 2; Hepatocyte Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Lymphokines; Male; Middle Aged; Multiple Myeloma; Nausea; Neoplasm Proteins; Primary Myelofibrosis; Quinolones; Salvage Therapy; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2003
Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jan-20, Volume: 24, Issue:3 Topics: Adolescent; Antineoplastic Agents; Bone Marrow; Child; Child, Preschool; Drug Administration Schedule; Drug Eruptions; Enzyme Inhibitors; Farnesyltranstransferase; Female; Gastrointestinal Tract; Humans; Male; Neurofibroma, Plexiform; Neurofibromatosis 1; Quinolones; Treatment Outcome	2006

Article

Year

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.

Blood, 2003, Mar-01, Volume: 101, Issue:5

Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Blast Crisis; Drug Administration Schedule; Drug Eruptions; Endothelial Growth Factors; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Fibroblast Growth Factor 2; Hepatocyte Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Lymphokines; Male; Middle Aged; Multiple Myeloma; Nausea; Neoplasm Proteins; Primary Myelofibrosis; Quinolones; Salvage Therapy; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2003

Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jan-20, Volume: 24, Issue:3

Topics: Adolescent; Antineoplastic Agents; Bone Marrow; Child; Child, Preschool; Drug Administration Schedule; Drug Eruptions; Enzyme Inhibitors; Farnesyltranstransferase; Female; Gastrointestinal Tract; Humans; Male; Neurofibroma, Plexiform; Neurofibromatosis 1; Quinolones; Treatment Outcome

2006